Abstract: The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, R4, R5, n and m have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.

Abstract: The present invention relates to new compounds useful for the stimulation of the production of antibodies. Said compounds comprises a saccharidic tumor antigen and a polymeric scaffold. The present invention also encompasses conjugated compounds useful in ELISA assay for the selection of antibodies against saccharidic antigens.

Abstract: New targeting or therapeutic compounds which can be incorporated into a composition of gas-filled microvesicles. The invention further relates to gas-filled microvesicles for diagnostic and/or therapeutic use comprising said compounds and to their method of use. The new compounds are compounds of formula M-S-T, wherein: M represents a component capable of associating with an envelope of a gas-filled microvesicle; T represents a component comprising a targeting ligand or a therapeutic agent; and S represents a component comprising at least two bissulfone groups.

Abstract: Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.

Abstract: Compounds of the formula: Wherein R is selected from the group consisting of H, NH2, and NHBoc; and R? is selected from the group consisting of H, CH2Ph and tBu, optionally de-protected. Such compounds may be conjugated with a suitable molecule able to interact with physiological systems; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203Pb, 67Ga, 68Ga, 72As, 111In, 113In, 90Y, 97Ru, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb, 153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, 111Ag, 199Au, 161Tb, 51Cr, 167Tm, 141Ce, 168Yb, 88Y, 165Dy, 166Dy, 97Ru, 103Ru, 186Re, 188Re, 99mTc, 211Bi, 212Bi, 213Bi, 214Bi, 105Rh, 109Pd, 117mSn, 177Sn and 199Au, as well as the salts thereof with physiologically compatible bases or acids.

Abstract: There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.

Abstract: The present invention relates to a novel class of paramagnetic ion-based contrast i agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic i profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.

Abstract: Compounds of general formula (I): with substituents as defined herein and their chelates with bi-trivalent ions of the metal elements of atomic numbers 20 to 31, 39, 42, 43, 44, 49, and 57 to 83, and radioisotopes chosen among 203Pb, 67Ga, 68Ga, 72As, 111In, 113In, 90Y, 97Ru, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb, 153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, 111Ag, 199Au, 161Tb, 51Cr, 167Tm, 141Ce, 168Yb, 88Y, 165Dy, 166Dy, 97Ru, 103Ru, 186Re, 99mTc, 211Bi, 213Bi, 214Bi, 105Rh, 109Pd, 177mSn, 177Sn and 199Au, as well as the salts thereof with physiologically compatible bases or acids.

Abstract: A vial enshrouded or contained in a protective covering which prevents emission of radiation form the vial contents, shielding the environment and personnel from irradiation. The vial optionally has a V-shaped bottom to allow withdrawal of a maximal amount of the fluid without inverting the vial. The vial is equipped with a vial access adapter having a fluid withdrawal spike which extends in to the V-shaped bottom. The vial access adapter may be vented or non-vented.

Abstract: The invention provides MRI detectable species of formula (I): Dp-Sn-Nm, wherein D is a MRI detectable moiety; S is a spacer; N is a molecule of a nutrient or pseudo-nutrient; n is 0 or an integer, m is an integer and p is an integer. These compounds are useful for internalizing into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalized in normal healthy cells thus allowing the diagnosis of tumors. The internalization of the MRI detectable moiety involves the nutrients or pseudo-nutrients transporting system. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion.

Abstract: Composition for diagnostic or therapeutic use which comprises an assembly comprising an active agent. The assembly comprises a liposome and a plurality of micellar components associated thereto, said micellar components being associated to the outer surface of the envelope of said liposome through a substantially electrostatic interaction, When an active compound is incorporated into the micelles, a substantial amount of said active compound can be linked to a singe liposome. Furthermore, the presence of the outer micellar layer allows to increase the residence time of said liposome in the blood stream.

Abstract: Methods for the preparation of multivalent constructs for therapeutic and diagnostic applications are provided. More specifically, novel methods for preparing multivalent constructs comprising the formula A-B-C-D-E-B?-F for therapeutic and diagnostic applications are provided which use a novel linker D comprising, in various embodiments, a dicarboxylic acid derivative such as, e.g., a glutaric acid bis N-hydroxysuccinimidyl ester or a derivative thereof; or a diamine derivative. The remaining components in the multivalent construct A-B-C-D-E-B?-F are defined as follows: A is a first peptide, B is a first branching group, C is an optional first spacer, E is an optional second spacer which may be the same as or different from said first spacer C, B? is an optional second branching group which may be the same as or different from said first branching group B, and F is a second peptide which may be the same as or different from said first peptide A.

Abstract: The present invention refers to a process for preparing a compound of formula (I) through a carboxymethylation reaction occurring in the presence of a suitable alkylating agent and of a base, without the need of monitoring the pH of the reaction environment. The compound of formula (I) is a useful intermediate in the preparation of diagnostic contrast agents for MRI techniques.

Abstract: One embodiment of the present invention includes a system comprising to determine a direction of tracking a fiber based on a vector corresponding to a largest value of a set of values for a tensor, if an anisotropy value of the tensor is greater than or equal to a first threshold; and to apply a weighted function to the vector of the tensor to select the direction of tracking the fiber, if the anisotropy value of the tensor is less than or equal to the first threshold and larger than or equal to a second threshold. In one embodiment, the system is to generate the weighted function comprises a linear interpolation to be performed on the vector. In one embodiment, a weight of the linear interpolation is in part dependent on the anisotropy value of the tensor, wherein the weight corresponds to the anisotropy value relative to the first threshold. One embodiment of the invention is also executable as a method.

Abstract: A protective cover and radionuclide generator assembly. The cover protecting inlet and outlet connections disposed on the radionuclide generator. The radionuclide generator having a distal end having a generally flat top surface. The protective cover removably fixed at the distal end and positioned over the generally flat top surface. The protective cover engaging with the radionuclide generator and providing an interference fit. The interference fit preventing the removal of the cover from the radionuclide generator, unless so desired by a user. The cover being made from a radioactive resistant polypropylene.

Abstract: A vial having a V-shaped bottom to minimize the amount of medical fluid left in the vial at the end of the fluid withdrawal process. The vial is equipped with a vial access adapter having a fluid withdrawal spike which extends into the V-shaped bottom. The vial access adapter may be vented or non-vented. When the medical fluid is a nuclear drug, the vial and vial access adapter is enshrouded in a protective container containing lead to provide a safety to medical personnel from irradiation.

Abstract: The present invention relates to remotely determining local physical parameters in a fluid-filled cavity (e.g. heart cavities, blood vessels, industrial container) by means of ultrasound waves and encapsulated or stabilised gas bubbles. A measuring method, a method of diagnostic ultrasound of the same and an apparatus for remotely determining ambient physical local parameters of a fluid-filled cavity are disclosed.

Abstract: A prefilled syringe of cartridge barrel having a tamper evident closure. Tamper evidence is provided by: a frangible tip seal which is integral with the tapered tip of the barrel; a frangible tip cap covering the tip, the tip seal and a portion of the distal end of the barrel; and an overwrap covering the frangible tip cap and the distal end of the barrel sealed to the distal end of the barrel by a tamper evident seal. The tapered tip is optionally equipped with a luer collar to receive an external luer connector. Alternatively, the tapered tip can be provided with a bore therethrough which can be closed with an elastomeric plug and the external connector can be a tubing conduit.

Abstract: A vial having a V-shaped bottom to minimize the amount of medical fluid left in the vial at the end of the fluid withdrawal process. The vial is equipped with a vial access adapter having a fluid withdrawal spike which extends into the V-shaped bottom. The vial access adapter may be vented or non-vented. When the medical fluid is a nuclear drug, the vial and vial access adapter is enshrouded in a protective container containing lead to provide a safety to medical personnel from irradiation.

Abstract: A syringe of improved ergonomics having an ellipsoidal barrel which contains an ellipsoidal plunger. The plunger consists of: a plunger tip of a rigid, non-elastomeric material which interfaces a medical fluid contained in the syringe barrel; and an elastomeric ring which slideably interfaces the inside wall of the syringe barrel. In one embodiment the plunger contains a plastic plunger insert which supports the elastomeric ring, the interior of which is provided with an ellipsoidal cavity. A self-aligning plunger rod having a ball portion on its distal end is inserted into the cavity of the plunger insert. The ball portion freely moves in the cavity and directs the external force exerted on the plunger rod in an axial direction.